How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/skin-and-skin-structure-proteus-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Skin and Skin Structure Proteus Infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Skin and Skin Structure Proteus Infection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Skin and Skin Structure Proteus Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Unasyn	SULBACTAM	Pfizer	beta Lactamase Inhibitor	Serine beta-lactamase-like protein LACTB, mitochondrial	1986-01-01
Fortaz	Ceftazidime	Pai Holdings Pharm	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 10 drugs in Skin and Skin Structure Proteus Infection
Bristol-Myers Squibb · 4 drugs in Skin and Skin Structure Proteus Infection
Merck & Co. · 2 drugs in Skin and Skin Structure Proteus Infection
Pai Holdings Pharm · 2 drugs in Skin and Skin Structure Proteus Infection
Pfizer · 2 drugs in Skin and Skin Structure Proteus Infection
Generic (originally Roche) · 1 drug in Skin and Skin Structure Proteus Infection
Assistance Publique - Hôpitaux de Paris · 1 drug in Skin and Skin Structure Proteus Infection
Novartis · 1 drug in Skin and Skin Structure Proteus Infection
Tel-Aviv Sourasky Medical Center · 1 drug in Skin and Skin Structure Proteus Infection
University Hospital, Lille · 1 drug in Skin and Skin Structure Proteus Infection
Poitiers University Hospital · 1 drug in Skin and Skin Structure Proteus Infection
Bayer AG · 1 drug in Skin and Skin Structure Proteus Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Skin and Skin Structure Proteus Infection:

Cite this brief

Drug Landscape (2026). Skin and Skin Structure Proteus Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/skin-and-skin-structure-proteus-infection. Accessed 2026-06-10.

Skin and Skin Structure Proteus Infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing